Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

President Donald Trump’s tariffs have two primary objectives. One is to rebalance the world trade order, which he believes is ...

Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses.

The stock market braces for a big week for earnings, economic news and trade war issues. Apple, Amazon, Pfizer and Chevron ...

The restricted mean survival time (RMST) analysis technique was introduced in health care research about 25 years ago and since then has become widely used in economics, engineering, business and ...

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Eli Lilly has unveiled a $2.5 billion deal to acquire ... as-yet-unnamed independent company that will be majority-owned by Scorpion's current shareholders with Lilly retaining a minority stake.

May. These duties won’t just be economically wasteful: They’ll pummel the U.S. health care system. Unlike the “reciprocal” ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

We also talk about today’s DNA-related advances that use machine learning to design tailored Cas9 proteins, and multiple sequencing technologies to study mutation rates in four generations of the same ...